HIV-1 p17 Activators

HIV-1 p17, a matrix protein of HIV-1, is critical in the virus's assembly and infection processes. While direct chemical activators of HIV-1 p17 are not typically highlighted, certain compounds can indirectly influence its activity or expression, primarily by impacting HIV-1 replication or reactivation of latent virus. Compounds like Prostratin, Disulfiram, Panobinostat, and Vorinostat are known to affect latent HIV-1 activation. These chemicals, through various mechanisms, can lead to an increase in HIV-1 replication, thereby potentially increasing the expression of viral proteins including p17.

Histone deacetylase inhibitors like Panobinostat, Vorinostat, and Romidepsin play a role in chromatin remodeling and can activate latent HIV-1. This activation can lead to an increase in the expression of HIV-1 proteins, including p17. BET bromodomain inhibitors like JQ1 and epigenetic modulators like GSK126 also have implications in HIV-1 activation and could impact p17 expression. Moreover, compounds like Ingenol Mebutate, Valproic Acid, Betulinic Acid, and Nicotinamide have been studied for their effects on latent HIV-1. By activating latent virus reservoirs, these compounds can lead to an increase in viral replication, which would include increased synthesis of p17. Bryostatin-1, a protein kinase C activator, has been explored for its potential role in HIV-1 activation, which can have implications for p17 levels.